{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360294645257535616.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.idcr.2020.e00837"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S2214250920301451?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S2214250920301451?httpAccept=text/plain"}}],"dc:title":[{"@value":"Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380294645257535619","@type":"Researcher","foaf:name":[{"@value":"Rania M. El-Lababidi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380294645257535618","@type":"Researcher","foaf:name":[{"@value":"Mohamad Mooty"}]},{"@id":"https://cir.nii.ac.jp/crid/1380294645257535617","@type":"Researcher","foaf:name":[{"@value":"Maria-Fernanda Bonilla"}]},{"@id":"https://cir.nii.ac.jp/crid/1380294645257535616","@type":"Researcher","foaf:name":[{"@value":"Nouran M. Salem"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"22142509"}],"prism:publicationName":[{"@value":"IDCases"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2020","prism:volume":"21","prism:startingPage":"e00837"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license","http://creativecommons.org/licenses/by-nc-nd/4.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S2214250920301451?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S2214250920301451?httpAccept=text/plain"}],"createdAt":"2020-05-21","modifiedAt":"2025-11-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360857593809025536","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.idcr.2020.e00837"},{"@type":"CROSSREF","@value":"10.1016/j.jneuroim.2021.577627_references_DOI_N2T9Jkm6RoSUTywKRNSbshhNxMf"}]}